Literature DB >> 12003588

The impact of atopy on neutrophil activity in middle ear effusion from children and adults with chronic otitis media.

David S Hurst1, Per Venge.   

Abstract

OBJECTIVE: To identify the relationship of neutrophil activity to allergy as reflected by the level of myeloperoxidase (MPO) in ears of atopic patients with chronic otitis media with effusion (OME) by objective testing.
DESIGN: Evidence of neutrophils was measured in the effusion of atopic patients with chronic OME. Atopy was determined by intradermal and/or in vitro testing of allergic reaction to 10 inhalants, 2 molds, and 5 foods.
SUBJECTS: Effusion MPO was measured prospectively in 138 ears from 106 consecutive patients with chronic OME.
RESULTS: A total of 86 (81%) of 106 patients with OME tested atopic by in vitro or in vivo testing. Excluding 36 ears with purulence, the mean MPO level was 3132 microg/L in 84 atopic vs 142 microg/L in 18 nonatopic ears (P<.001). A total of 78 (90%) of 87 patients with OME were atopic.
CONCLUSIONS: The surprising finding of marked elevation of effusion MPO in atopic patients but very low levels in nonatopic patients (P < .001) suggests that atopy may contribute to elevated levels of neutrophil activity in OME. An atopic patient may respond differently from a nonatopic one to the microbial or viral products of acute inflammation owing to the presence of primed inflammatory cells. This study provides confirmation on a cellular level that neutrophils are an integral part of the inflammatory process in OME to a disproportionate degree among atopic patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12003588     DOI: 10.1001/archotol.128.5.561

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  8 in total

1.  Role of nasal allergy in chronic secretory otitis media.

Authors:  Zdenek Pelikan
Journal:  Curr Allergy Asthma Rep       Date:  2009-03       Impact factor: 4.806

Review 2.  Can vaccination against pneumococci prevent otitis media with effusion?

Authors:  Aly M N El-Makhzangy; Naema M Ismail; Salma B Galal; Tamer S Sobhy; Amal A Hegazy
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-03-03       Impact factor: 2.503

3.  Evaluation of nasopharyngeal microbial flora and antibiogram and its relation to otitis media with effusion.

Authors:  Navid Nourizadeh; Kiarash Ghazvini; Vahideh Gharavi; Niloufar Nourizadeh; Rahman Movahed
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-05-01       Impact factor: 2.503

Review 4.  Glucocorticosteroids in allergic inflammation: clinical benefits in otitis media with effusion.

Authors:  Ingeborg Dhooge; Katia Verbruggen; Liesbet Vandenbulcke
Journal:  Curr Allergy Asthma Rep       Date:  2006-07       Impact factor: 4.806

5.  Pro-inflammatory interleukins in middle ear effusions from atopic and non-atopic children with chronic otitis media with effusion.

Authors:  Beata Zielnik-Jurkiewicz; Wanda Stankiewicz-Szymczak
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-06-16       Impact factor: 2.503

6.  Characterization of mucoid and serous middle ear effusions from patients with chronic otitis media: implication of different biological mechanisms?

Authors:  Stéphanie Val; Marian Poley; Krueger Anna; Gustavo Nino; Kristy Brown; Marcos Pérez-Losada; Heather Gordish-Dressman; Diego Preciado
Journal:  Pediatr Res       Date:  2018-05-28       Impact factor: 3.756

7.  Purification and characterization of microRNAs within middle ear fluid exosomes: implication in otitis media pathophysiology.

Authors:  Stéphanie Val; Stephanie Jeong; Marian Poley; Anna Krueger; Gustavo Nino; Kristy Brown; Diego Preciado
Journal:  Pediatr Res       Date:  2017-02-03       Impact factor: 3.756

8.  Proteomic Characterization of Middle Ear Fluid Confirms Neutrophil Extracellular Traps as a Predominant Innate Immune Response in Chronic Otitis Media.

Authors:  Stephanie Val; Marian Poley; Kristy Brown; Rachel Choi; Stephanie Jeong; Annie Colberg-Poley; Mary C Rose; Karuna C Panchapakesan; Joe C Devaney; Marcos Perez-Losada; Diego Preciado
Journal:  PLoS One       Date:  2016-04-14       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.